Global Pharmaceutical Drug Delivery Market Drivers
Increasing approval of new drugs from U.S. FDA is expected to drive growth of the global pharmaceutical drug delivery market. For instance, in April 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Duobrii (contains-halobetasol propionate and tazarotene), which is used for the treatment of plaque psoriasis. It is manufactured by Ortho Dermatogics Company.
Furthermore, new product launches is expected to boost the global pharmaceutical drug delivery market. For instance, in August 2018, Sanofi Genzyme launched new drug (Aubagio) for the treatment of multiple sclerosis. Aubagio offers once-a-day treatment and ease of convenience for the patient.
Moreover, in April 2019, Pfizer launched trastuzumab (trazimera) for the treatment of metastatic HER2 (Human Epidermal Growth Factor 2)-positive breast cancer and HER2-positive metastatic gastric cancer. Hence, these products are expected to boost the global pharmaceutical drug delivery market.
Global Pharmaceutical Drug Delivery Market Restraints
Drug shortage is projected to hamper growth of the global pharmaceutical drug delivery market. For instance, according New York Times report in February 2019, Buspirone HCL Tablets -7.5mg manufactured by Accord Healthcare Inc. was on shortage, due to high demand for the drug for the anxiety treatment.
Furthermore, in September 2018, Union Health Ministry of India banned 328 FDC (Fixed Dose Composition) drugs due to irrational use of FDC drugs. Some other examples of banned drugs-Aceclofenac (SR) + Paracetamol 750, Aceclofenac + Paracetamol + Famotidine, naproxen plus paracetamol. Such ban of drugs will affect growth of global pharmaceutical drug delivery market.
Pharmaceutical Drug Delivery Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients